Single‐cell transcriptomic analysis uncovers intratumoral heterogeneity and drug‐tolerant persister in ALK ‐rearranged lung adenocarcinoma (2023)

Dear Editor, Non-small cell lung carcinoma (NSCLC) accounts for more than 85% of all lung cancers [1]. Lung adenocarcinomas (ADCs) arising from never-smokers have been frequently found to be associated with oncogenic driver mutations, including anaplastic lymphoma kinase (ALK) rearrangement. Echinoderm microtubule-associated protein-like 4 (EML4) is the most common fusion partner of the ALK gene [2]. Tyrosine kinase inhibitors (TKIs) are currently the first-line treatment for advanced EML4-ALK-rearranged lung ADC. However, NSCLC patients treated with TKIs commonly exhibit disease progression within one to two years of treatment due to the development of acquired resistance [3]. In addition, genotypic diversity among subpopulations of cancer cells contributes to the development of drug insensitivity to other therapeutic options, such as immunotherapy [4], so drug resistance or insensitivity presents the greatest challenge in NSCLC maintenance therapy. In this study, we hypothesized that drug-tolerant persister (DTP) cells pre-exist among heterogeneous tumor subpopulations and confer drug insensitivity. Two ALK-rearranged lung cancer organoids (LCOs) (TS485T-organoids (O) derived from a resected primary tumor and FA34-O derived from malignant pleural effusion) were exposed to escalating concentrations of ALK-TKIs (Supplementary Figure S1A), leading to the emergence of acquired resistance in four subsequently established drug-resistant LCOs TS485T-O-C, TS485T-O-A, FA34-O-C, and FA34-O-A (-S = drug sensitive; -C = crizotinib resistant; -A = alectinib resistant) (Supplementary Figure S1B). This mimicked the clinical observation of ALK-rearranged lung ADC tumors developing acquired resistance after a certain period of ALK-TKI treatment. Single-cell RNA-sequencing (scRNA-seq) analysis of two TKI-sensitive and four TKI-resistant tumor organoids of TS485T-O and FA34-O was performed individually. At least 5,000 cells per sample with approximately 12,000 to 31,000 unique molecular index (UMI) counts per cell were sequenced (Supplementary Table S1). Uniform Manifold Approximation and Projection (UMAP) dimensionality reduction analysis allowed the visualization of intratumoral heterogeneity within two groups of samples (Figure 1A-D). Ten clusters from the TS485T-O model (Figure 1A-B) and 21 clusters from the FA34-O model (Figure 1C-D) were partitioned. In both TS485T-O and FA34-O groups, cells from drug-sensitive and drug-resistant LCOs were grouped into separate clusters according to their transcriptomic profiles (Supplementary Figure S2A-B). Differential gene expression (DGE) analysis of drug-resistant and drug-sensitive TS485T-O LCOs revealed that the interleukin-17 (IL-17) signaling pathway was enriched in both crizotinib-resistant and alectinib-resistant tumor organoids (Supplementary Figure S2C-D). Crizotinib-resistant tumor organoids of TS485T-O were characterized by overexpression of the IL-17 pathway component, chemokine (C-C motif) ligand 20 (CCL20) (Figure 1E). CCL20 has been shown to play a role in modulating the tumor immune microenvironment [5]. In alectinib-resistant tumor organoids of TS485T-O, besides the activated IL-17 pathway, upregulation of ribosomal protein L10 (RPL10), nicotinamide phosphoribosyltransferase (NAMPT) and anterior gradient-2 (AGR2) were observed (Figure 1F), and the functions of these genes in lung cancer were mentioned in previous studies [6, 7]. In contrast, we found that the actin cytoskeleton regulatory pathway was downregulated in both FA34-O crizotinib-resistant and alectinib-resistant tumor organoids (Supplementary Figure S2E-F). To identify subpopulations of DTP cells and their gene signatures that might have been previously masked in bulk RNA sequencing, the top differentially expressed genes in different clusters were plotted in the single-cell transcriptomic profiles (Supplementary Figure S2G-H). CCL20 was highly expressed in most TKI-resistant TS485T-O cells, but some clusters with distinctive high expression of CCL20 (clusters 4 and 10) were found in TKI-sensitive TS485T-O models (Figure 1I, upper panel). In contrast, CCL20 was weakly expressed in most FA34-O cells, but its expression was higher in cluster 6 (Figure 1I, lower panel). This striking difference in CCL20 expression between the TS485T-O model (derived from a resected primary tumor) and the FA34-O model (derived from a TKI-naive metastatic tumor) suggest that CCL20 might play an important role in modulating the tumor immune microenvironment in primary tumors. The IL-17 signaling pathway and cytokine-cytokine receptor interaction were highly enriched in TS485T-O cluster 4 (Figure 1I, upper right panel), which is mainly enriched in drug-sensitive cells, and a similar enrichment pattern was observed in the DGE analysis of drug-resistant cells (Supplementary Figure S2C-D). In addition, the CCL20-expressing cluster (cluster 6) in the FA34-O model (Figure 1I, lower panel) was also characterized by enrichment of the Tumor necrosis factor (TNF) signaling pathway, which was also found in TS485T-O cluster 4 (Figure 1I, upper panel) but not in the DGE analysis of the FA34-O model (Supplementary Figure S2E-F). These data strongly supported the pre-existence of DTP subpopulations. Single-cell transcriptomic analysis revealed intratumoral heterogeneity in ALK-TKI-resistant LCOs. UMAP representation of TS485T-O (A-B) or FA34-O (C-D) drug-sensitive or drug-resistant cells colored by the cell of origin (A, C) or by clusters (B, D). Top dysregulated genes and pathways when comparing TS485T-O (E-F) or FA34-O (G-H) models with crizotinib or alectinib-resistant LCOs with sensitive LCOs. CCL20-expressing subpopulations and their enriched signaling pathways in TS485T-O (I, upper panel) or FA34-O (I, lower panel) models. (J) A tumor formation assay was performed on ICAM-1 low- or high-expressing cells separated by flow cytometry. The number of spheres was counted after two weeks of cell seeding. (K) CCL20 levels in conditioned medium were assayed by ELISA 4 days after ICAM-1 sorting. (L) mRNA expression levels of CCL20 and cancer stem cell markers (ALDH1A1, POU5F1, NANOG, and PROM1) in cells with low, medium or high ICAM-1 expression were assayed by real-time RT‒PCR after cell sorting. (M) Sensitivity to crizotinib (0.5 or 5 μmol/L) treatment for 3 days in cells with low, medium, or high ICAM-2 levels were determined by cell viability assay. (N) Colocalization of ICAM-1+ (pink) tumor cells and RORƔt+ (orange) Th17 cells in ALK-rearranged primary NSCLC tumor FFPE visualized by multiplexed immunofluorescence staining (N = 12). Tumor cells were located by TTF-1 (green) staining, and nuclei were counterstained with DAPI (blue). Representative images of co-localization from two resected tumor tissues, TS485 and TS281, are shown. The number of RORƔt+ lymphocytes and ICAM-1+ tumor cells in the tumor area were counted. (O) Association of ALK-rearranged lung ADC patient survival with plasma levels of CCL20 (ICAM-1low, n = 15; ICAM-1high, n = 4). *P < 0.05; **P < 0.01; ***P < 0.001. (P) Hypothetical model showing the role of CCL20 and its downstream mechanism in modulating the tumor immune microenvironment. Subpopulations of drug-resistant ICAM-1high tumor cells release CCL20 to recruit Th17 lymphocytes into the tumor microenvironment. Th17 lymphocytes in the tumor bed release IL-17, which can prevent the infiltration of CD8+ cytotoxic T cells. IL-17 can also induce EMT and metastasis of tumor cells. Abbreviations: Anterior gradient 2 (AGR2); Chemokine (C-C motif) ligand 20 (CCL20); BPI fold containing family A, member 1 (BPIFA1); Cancer susceptibility candidate 1 (CASC1); Cell division cycle 20B (CDC20B); Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6); Cilia and flagella associated protein 126 (CFAP126); Coiled-Coil Domain Containing 170 (CCDC170); Coronin 2A (CORO2A); C-X-C motif chemokine ligand 8 (CXCL8); Dynein axonemal assembly factor 1 (DNAAF1); Dynein axonemal heavy chain 7 (DNAH7); EF-hand domain family member B (EFHB); Ferritin heavy chain 1 (FTH1); GINS complex subunit (GINS1); Hypoxia-inducible factors (HIF); Leucine Rich Repeat Containing 46 (LRRC46); Matrix metallopeptidase 1 (MMP1); Meiosis specific nuclear structural 1 (MNS1); Nicotinamide phosphoribosyltransferase (NAMPT); Nucleotide oligomerization domain (NOD); Myocardial infarction associated transcript (MIAT); Paternally Expressed 10 (PEG10); PIH1 domain containing 3 (PIH1D3); Primary cilia formation (PIFO); Prosaposin (PSAP); Ras-proximate-1 (RAP1); Radial spoke head component 1 (RSPH1); Regulator of cell cycle (RGCC); Rho family GTPase 1 (RND1); Rhophilin associated tail protein 1 like (ROPN1L); Ribosomal Protein L10 (RPL10); Insulin like growth factor binding protein 5 (IGFBP5); Intercellular adhesion molecule 1 (ICAM-1); Interleukin-17 (IL-17); S100 Calcium Binding Protein A9 (S100A9); Trefoil factor 1 (TFF-1); Tetraspanin 1 (TSPAN1); Threonine tyrosine kinase (TTK); T helper-17 lymphocytes (Th17); WAP four-disulfide core domain protein 2 (WFDC2) CCL20, mainly produced by mucosal lymphoid tissues, is a chemokine that directs lymphocyte migration toward epithelial cells. It has been previously reported that CCL20 expression might contribute to the progression of many cancers [8]. CCL20 is a secreted protein, so cells cannot be sorted based on the expression of this protein. To characterize the DTP subpopulations, we further explored the DGE profiles of TS485T-O cluster 4 and FA34-O cluster 6 and identified surface markers coexpressed with CCL20. We found that intercellular adhesion molecule 1 (ICAM-1; CD54), a surface glycoprotein usually expressed on endothelial cells but previously identified as a cancer stem cell (CSC) marker [9, 10], was also highly expressed in CCL20-expressing clusters (Supplementary Figure S3). To investigate the tumorigenicity of tumor subpopulations expressing different levels of ICAM-1, tumor sphere formation assays and qRT‒PCR were performed on ICAM-1high, ICAM-1medium and ICAM-1low cells separated by flow cytometry. TS485T-O cells with high ICAM-1 demonstrated a much stronger sphere formation ability (Figure 1J). Cells with high ICAM-1 expression released more CCL20 than ICAM-1low cells (Figure 1K). We also found that ICAM-1high cells expressed higher levels of CSC marker genes, including aldehyde dehydrogenase 1 family member A1(ALDH1A1), POU Class 5 Homeobox 1 (POU5F1), Homeobox protein NANOG (NANOG) and Prominin 1 (PROM1) (Figure 1L), and were characterized by a stronger resistance to crizotinib (Figure 1M). All these data indicate the strong tumorigenicity of ICAM-1high and CCL20-releasing tumor cell subpopulations in ALK-rearranged lung ADCs. Analysis in the Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) cohort showed that higher tumor CCL20 expression levels were associated with poor survival (Supplementary Figure S4). A statistically significant difference in CCL20 expression levels was found when comparing normal lung tissues with tumor tissues from non-smokers. These results suggested that tumor CCL20 expression may be a prognostic biomarker in non-smokers with NSCLC. To evaluate the role and clinical relevance of the CCL20-expressing subpopulation in primary tumors that could be DTP cells, multiplexed immunofluorescence staining was used to evaluate the spatial co-localization of ICAM-1+ tumor cells and retinoid-related orphan receptor-γ+ T helper 17 (RORɣt+ Th17) lymphocytes in resected primary tumor tissues (Figure 1N). CCL20 is a chemokine that directs chemokine receptor 6 (CCR6)-expressing lymphocytes, including Th17 lymphocytes, to migrate toward epithelial cells. The frequency of ICAM-1+ tumor cells correlated positively with the number of RORɣt+ Th17 lymphocytes, suggesting that Th17 lymphocytes are actively recruited into the tumor microenvironment by ICAM-1+ tumor subpopulations. In addition, plasma levels of CCL20 from 21 patients with advanced ALK-rearranged NSCLC were assayed with enzyme-linked immunosorbent assay (ELISA). Similar to tumor CCL20 expression in TCGA-LUAD, high plasma CCL20 was associated with poor survival (Figure 1O). These data suggested that although CCL20 might not be responsible for mediating TKI resistance, infiltration of Th17 lymphocytes may be key to the development of drug insensitivity to immune checkpoint inhibitor therapy (Figure 1P). In conclusion, our scRNA-seq data identified a subpopulation of ALK-TKI-resistant DTP lung ADC cells that might contribute to the development of TKI resistance and modulation of the tumor immune microenvironment. Hoi-Hin Kwok: laboratory experiment coordination and supervision and manuscript writing. Huiyu Li and Luc Girard: single-cell RNA computational analysis. Jiashuang Yang, Junyang Deng, and Nerissa Chui-Mei Lee: laboratory experiments. Timmy Wing-Kuk Au, Alva Ko-Yung Sit and Michael Kuan-Yew Hsin: surgical management of recruited subjects. Lydia Wai-Ting Cheung and Stephanie Kwai-Yee Ma: assistance in the establishment of LCOs. Junya Fujimoto and Ignacio Ivan Wistuba: cytological and histological evaluation. Boning Gao and John Dorrance Minna: data analysis and manuscript drafting. David Chi-Leung Lam: overall conceptualization, manuscript drafting and revision, and analysis of results. Not applicable. JDM receives licensing royalties from the United States National Institute of Health and the University of Texas Southwestern Medical Center at Dallas for the distribution of human tumor cells and human bronchial epithelial cell strains. The other authors declare that they have no competing interests. The research work described in this report was supported by the Lee and the Ho Families Respiratory Research Fund (research donation to DCL). National Natural Science Foundation of China (Grant# 82022078 to LWTC). United States National Cancer Institute Lung Cancer Specialized Program in Research Excellence (SPORE) P50 (CA070907 to JDM). The study protocol was approved by the Ethics Committee of the University of Hong Kong and the Hong Kong Hospital Authority of Hong Kong West Cluster Institutional Review Board (IRB Reference Number UW 16-104). Informed consent was obtained from all the participants. Not applicable. All the data supporting the conclusions of this article are included within the article. Data for single-cell sequencing were deposited in National Center for Biotechnology Information Gene Expression Omnibus NCBI-GEO repository (GSE223779). Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.